Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
New Possibilities of Treatment for Panic Attacks in Elderly Patients: Escitalopram Versus Citalopram
Purpose : Panic attacks may represent additional therapeutic problems in the elderly . The utility of citalopram in panic attacks has been widely investigated . Here , we compare the efficacy and safety of citalopram , with its S-enantiomer escitalopram at half dosage as to citalopram , in elderly patients who have panic attacks . Methods : This was an open community-based study . Forty patients who have panic attacks , according to Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition criteria , were enrolled . Fifty percent of the patients were assigned for 8 weeks ' treatment with escitalopram , and the remaining 50 % were assigned to treatment with citalopram . The primary outcome measure was the weekly rate of panic attacks . The secondary outcome measures were the Hamilton scale for anxiety and depression and the Cooper Disability Scale . Analysis of variance by repeated measures was applied to calculate differences between groups . Results : A similar decrease in weekly rate of panic attacks , in the scores of Hamilton Scale for anxiety and depression and in the Cooper Disability Scale scores , was observed in both groups after 8 weeks , but a significant variation of outcome measures from baseline was observed already after 2 weeks in the escitalopram group ( P < 0.001 ) and only after 4 weeks in the citalopram group ( P < 0.01 ) . Conclusions : Escitalopram could be considered among the drugs of first choice in elderly patients with panic attacks because of its good efficacy and safety and for the advantage of reducing the total dose and of a more rapid onset of action as compared with citalopram , although further studies are needed to confirm these results
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .